Annual healthcare costs jump by almost $25,000 with targeted therapy for atopic dermatitis that avoided costs from reduced hospitalizations and ER visits only partly offset, according to recently reported research findings.
News|Articles|August 1, 2004
Imiquimod for superficial basal cell carcinoma
Although the mechanism of action of imiquimod is unknown, an open-label study suggests that the drug may act by increasing the filtration of lymphocytes, dendritic cells, and macrophages into the tumor lesion. Imiquimod was approved on July 14, 2004, for an expanded indication to include the treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults.
Advertisement
Advertisement
Related to this article
Findings from an analysis of IQVIA claims data show a prevalence rate that is five times lower than previous reports. Some of the discrepancy could be chalked up to the difference between using claims data instead of self-reporting by survey respondents.
Health plans should be using data, digital tools and human support to identify potential disruptions early, and whether a member is changing plans or managing a new health condition, the experience should feel guided rather than overwhelming.
Pretax adjusted income from operations from Express Scripts, Cigna's pharmacy benefit manager, fell by 21.5% compared with the third quarter of 2025, while income from operations of its specialty drug business jumped by 15%.
Annesha White, Pharm.D., M.S., Ph.D., and Fredrick Manasseh, Pharm.D., MBA, BCGP, explain where AI helps managed care pharmacy, where bias creeps in and what skills pharmacists need to oversee it.
Teva’s Weltruza delivers olanzapine monthly under the skin, with no loading doses, oral supplementation or post-injection monitoring required.
Value-based care has scored some cost-saving successes, says Christopher Stanley, M.D., MBA, president of Henry Ford Health's Populance. Health systems that build their own value-based care strategy, rather than adopting particular models one by one, will be in the best position to succeed, he says.
The second half of our conversation with Christopher Stanley, M.D., MBA, the president of Henry Ford Health's Populance and the newest member of the Managed Healthcare Executive editorial advisory board.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
WHO adds two Bundibugyo vaccines to Ebola trial in the DRC
2
Christopher Stanley, M.D., MBA, on the early population health wins of Henry Ford Health's Populance
3
Cigna’s third-quarter earnings show a drop in income from its pharmacy benefit business
4
FDA approves Weltruza, first once-monthly subcutaneous olanzapine injection for schizophrenia
5